An Evidence-Based Perspective (drlewis.com, January 4, 2026) Clinical perspective from practicing psychiatrist on integrating GLP-1s into psychiatric care, citing safety data and metabolic-mental health connection
Common side effects (affecting 20-40% of users) Nausea is the most frequently reported side effect, affecting roughly 30 to 40 percent of patients at some point during treatment
Moreover, in a study of 1200 patients admitted at ICU, of whom 203 were affected by diabetes, intensive insulin therapy significantly reduced the rate of morbidities, including newly acquired kidney injury and the need of mechanical ventilation, with accelerated discharge from the ICU and the hospital
At this time, retatrutide, one of the best-known triple hormone receptor agonists, is still investigational and has not been approved by any regulatory agency for routine patient use
The prescription drugs need injections, but the supplements are usually found in pills or tablets
Who Should and Shouldn't Use Compounded Semaglutide: Provider-Led Eligibility Ideal candidates are adults with BMI 30 or BMI 27 with weight-related comorbidities, no history of medullary thyroid cancer, and stable kidney and pancreatic function
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
